Dipicolylamine-based Nanoparticles for Delivery of Ligands


Many potential nucleic acid therapeutics have not transitioned from the research laboratory to clinical application in large part because delivery technologies for these therapies are not effective. Most nucleic acid delivery technologies are lipid-based or positively charged and require chemical or physical conjugation with the nucleic acid. These delivery systems are often therapeutically unacceptable due to toxicity or immune system reactivity. The present technology is a nanoparticle complex, containing a polymer substrate, such as a hyaluronic acid, and Zn2+-dipicolylamine (Zn-DPA), that associates selectively with the nucleic acid phosphodiester groups. This complex functions as a simple, easy to scale-up, cost effective, low toxicity delivery system for potential nucleic acid therapeutics, such as siRNA molecules. It may also be capable of co-delivering other small molecule drugs.

Potential Commercial Applications: Competitive Advantages:
  • Drug delivery
  • Gene therapy
 
  • Efficient
  • Easy to scale-up
  • Cost effective
  • Low toxicity


Development Stage:
  • Early-stage
  • In vivo data available (animal)


Inventors:

Xiaoyuan (Shawn) Chen (NIBIB)  ➽ more inventions...

Seulki Lee (NIBIB)  ➽ more inventions...

Ki Young Choi (NIBIB)  ➽ more inventions...


Intellectual Property:
US Application No. 61/729,159
US Application No. 14/086,111

Publications:
Liu G, et al. PMID 22110006

Collaboration Opportunity:

The National Institute of Biomedical Imaging and Bioengineering is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Henry S. Eden, M.D., Ph.D. at edenh@mail.nih.gov.


Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-066-2012/0
Updated: Sep 17, 2015